Nobias Therapeutics is a clinical-stage company developing novel small-molecule therapeutics for rare diseases. The firm has unique access to genomic and health datasets and collaborates with pediatric academic medical centers across North America to advance drug discovery for genetically-defined rare diseases.

Nobias Therapeutics

Nobias Therapeutics | 706 followers on LinkedIn. Clinical-stage company developing novel small molecule therapeutics for rare diseases | Nobias Therapeutics is a clinical-stage company developing novel small molecule therapeutics for rare diseases. Our unique access to rich genomic and health datasets and strong relationships with pediatric academic medical centers across North America allow us to rapidly advance drug discovery for genetically-defined rare diseases, with an initial focus on pediatric indications, but expansion opportunities in adults and non-rare indications.

Biotech Professional - Strategy, Planning, Operations and Business Development

Patrick Dougherty

Bruce Goldsmith

at The Children's Hospital of Philadelphia

Hakon Hakonarson

Platform Engineer at Nobias Therapeutics

Abhishek Shakya

Thanks to the MEC team for a great event. Nobias is incredibly lucky to be part of the MEC portfolio and to have the support of such a great team!

Thanks again to the team at the LDV Vision Summit ( https://lnkd.in/dQyE7b9 ) for the opportunity for our CEO, Neil Inala , to speak with Olga Troyanskaya , Elizabeth Neumann , and moderator Laura Smoliar about advancements in visual tech and machine learning in the life sciences. For those who were not able to tune into the summit live, the transcript and video are now posted here: https://lnkd.in/d7UPuTZd

We've recently been accepted into the NVIDIA Inception program for startups. We're very excited by all the opportunities, resources, and capabilities this amazing program unlocks for us. Thanks very much to the team at NVIDIA for all their help! https://lnkd.in/ev2sJWeu

Nobias CEO Neil Inala will join a stellar Life Sciences Panel at the 2024 LDV Capital #LDVVisionSummit tomorrow! #AI advances are revolutionizing our world and #medicine and #drugdevelopment will be no different. Check out the agenda and register here: https://lnkd.in/dQyE7b9

If you are interested in connecting with Nobias at the BIO CEO and Investor Conference to discuss the results of our recent phase II clinical trial in 22q11 deletion syndrome (NB-001), our lymphatic anomalies program (NB-002), or to discuss other drug development opportunities using our cutting-edge generative-AI based target and molecule discovery platform, please reach out to us via LinkedIn or via the conference reservation system.

Our CEO Neil Inala recently attended the AI-Driven Drug Discovery Summit in Boston. It was a great couple of days with many interesting presentations from groups at the forefront of the use of AI techniques in drug discovery. The talks were well-attended and the questions asked were quite insightful.

November is 22q Awareness Month in the US ( https://lnkd.in/gKNHcDqm ); and November 22nd is 22q Awareness Day in Europe. We join the 22q11.2 Syndromes community ( http://www.22q.org/ ) to build awareness about 22q11.2 deletion and duplication as we recognize the incredible perseverance of this community in striving to overcome the many obstacles they face. Nobias is committed to advancing our clinical program for the treatment of certain neuropsychiatric conditions associated with #22q . We thank the many patients and families that have been part of our development journey to date. #22qfamily

DNSSEC

Amazon

Microsoft Exchange Online

Office 365 Mail

GoDaddy DNS

Brian Halak

Neil Inala

J. Patrick Dougherty

Consulting COO

Aleksey Krylov

Consulting CFO

Therapeutics Companies With Fewer Than 1000 Employees (Top 10K)

Private Northeastern US Companies (Top 10K)

Private New Jersey Companies (Top 10K)

Health Care Companies With Fewer Than 50 Employees (Top 10K)

Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children. It focuses on discovering the genetic basis for rare diseases and develops drugs that can intervene in the affected pathways, enabling parents to help their infants become healthier.

Series A - Nobias Therapeutics

Princeton

New Jersey

United States

North America

Nobias Therapeutics on LinkedIn: Nobias Therapeutics Joins NVIDIA Inception Program for Startups

Nobias Therapeutics Announces Phase 2 Clinical Trial Results for NB-001 at 52nd Child Neurology Society Annual Meeting

Nobias Therapeutics Announces Acceptance of Late-Breaking Abstract and Presentation of Phase 2 Clinical Data for NB-001 at 52nd Child Neurology Society Annual Meeting

An investigational metabotropic glutamate receptor (mGluR) modulator for treating neuropsychiatric symptoms in children with 22q11.2 Deletion Syndrome (22q11DS).

A MEK inhibitor in pre-clinical development for treating vascular anomalies caused by abnormal growth of blood vessels.

A suite of AI/ML-based drug discovery tools for early ideation, insight development, and chemical optimization, integrated into a single platform.

Philippines

Asia

India

Nobias Therapeutics is a clinical-stage company developing novel small-molecule therapeutics for rare diseases, focusing initially on pediatric indications and expanding to adults and non-rare indications. This description is self-described.

news impact assignment basic	general
public peers	general	Nov 11, 2024 6:34 PM	035179e5
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 11, 2024 6:34 PM	6dae11fd
crunchbase trigger	general	Nov 27, 2024 12:50 PM	8366a0a0
crunchbase profile	general	Nov 28, 2024 9:03 AM	92791193
li profile	general	Nov 11, 2024 6:34 PM	330357b0
translate crunchbase fundingrounds	general	Nov 28, 2024 10:19 AM	9faf5dd8
peers	general	Nov 11, 2024 6:34 PM	b7e50bd5
news basic	general	Nov 11, 2024 6:34 PM	79c6c371
bundesanzeiger	filings
financials download nd	financials
private financials	financials

NOBI

COM:NOBIASTX

Nobias Therapeutics